Friday, 16 October 2026European Markets

ABC ARBITRAGE And ASR NEDERLAND Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - abc arbitrage (abca.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
abc arbitrage (abca.pa) €4.82 8.76% 13.59%
asr nederland (asrnl.as) €42.69 6.5% 39.77%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. abc arbitrage (abca.pa)

8.76% forward dividend yield and 13.59% return on equity

abc arbitrage sa, together with its subsidiaries, engages in the development of arbitrage strategies for liquid assets worldwide. it develops liquidity, statistical, risk, and derivatives arbitrage strategies; and provides asset and portfolio management services. the company was incorporated in 1995 and is based in paris, france.

earnings per share

as for profitability, abc arbitrage has a trailing twelve months eps of €0.37.

pe ratio

abc arbitrage has a trailing twelve months price to earnings ratio of 13.01. meaning, the purchaser of the share is investing €13.01 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.59%.

volatility

abc arbitrage's last week, last month's, and last quarter's current intraday variation average was a positive 0.28%, a negative 0.18%, and a positive 1.36%.

abc arbitrage's highest amplitude of average volatility was 1.97% (last week), 1.32% (last month), and 1.36% (last quarter).

dividend yield

according to morningstar, inc., the next dividend payment is on dec 5, 2023, the estimated forward annual dividend rate is 0.41 and the estimated forward annual dividend yield is 8.76%.

more news about abc arbitrage.

2. asr nederland (asrnl.as)

6.5% forward dividend yield and 39.77% return on equity

asr nederland n.v. provides insurance, pensions, and mortgages products for consumers, self-employed persons, and companies. it operates through five segments: non-life, life, asset management, distribution and services, and holding and other. the company offers health, life, pension, funeral expense, and occupational disability insurance products; and non-life insurance products, including road traffic, fire, third-party liability and legal assistance insurance. it also provides financial intermediary services; and develops real estate properties, as well as operates as an asset manager for third parties. asr nederland n.v. offers its products under the loyalis, ditzo, europeesche verzekeringen, a.s.r. asset management, ardanta, and a.s.r. brand names. the company was formerly known as fortis verzekeringen nederland n.v. and changed its name to asr nederland n.v. in october 2008. asr nederland n.v. was founded in 1720 and is headquartered in utrecht, the netherlands.

earnings per share

as for profitability, asr nederland has a trailing twelve months eps of €17.72.

pe ratio

asr nederland has a trailing twelve months price to earnings ratio of 2.41. meaning, the purchaser of the share is investing €2.41 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 39.77%.

volatility

asr nederland's last week, last month's, and last quarter's current intraday variation average was a negative 0.27%, a negative 0.21%, and a positive 0.97%.

asr nederland's highest amplitude of average volatility was 0.73% (last week), 0.67% (last month), and 0.97% (last quarter).

more news about asr nederland.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com